Schmidt PT, Ljung T, Hartmann B, Hare KJ, Holst JJ, Hellstrm PM (2005) Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY
This glucagon-like peptide-1 (GLP-1) receptor agonist, through its multifaceted action, not only improves glycemic control but also facilitates weight reduction, thus addressing two critical components of metabolic syndrome
They were briefing-document proposals rather than final determinations at this articles review date
However, remember that sustainable weight loss is a holistic endeavor encompassing lifestyle changes, not solely medication